Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
SAPPHIRE
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
- NCT03906071 ↗
- Terminated
- Mirati Therapeutics Inc.
- Focused
We haven't built an HCP commentary report on SAPPHIRE (sitravatinib plus nivolumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SAPPHIRE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Nivolumab; Sitravatinib; Docetaxel
- Arms
- Nivolumab and Sitravatinib · Experimental
- Docetaxel · Active comparator
- Enrollment
- 577
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Mirati Therapeutics Inc. with Bristol-Myers Squibb
- Start
- Jul 15, 2019
- Primary completion
- Mar 20, 2023
- Results posted
- Yes
- Registry record
- NCT03906071 · updated Sep 30, 2026